IL281802A - Use of an inhibitor of an ent family transporter in the treatment of cancer and combination thereof with an adenosine receptor antagonist - Google Patents
Use of an inhibitor of an ent family transporter in the treatment of cancer and combination thereof with an adenosine receptor antagonistInfo
- Publication number
- IL281802A IL281802A IL281802A IL28180221A IL281802A IL 281802 A IL281802 A IL 281802A IL 281802 A IL281802 A IL 281802A IL 28180221 A IL28180221 A IL 28180221A IL 281802 A IL281802 A IL 281802A
- Authority
- IL
- Israel
- Prior art keywords
- cancer
- inhibitor
- treatment
- combination
- receptor antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862737717P | 2018-09-27 | 2018-09-27 | |
BE20180115A BE1026612B1 (en) | 2018-09-27 | 2018-09-27 | USE OF AN ENT FAMILY CARRIER INHIBITOR IN THE TREATMENT OF CANCER AND COMBINATION THEREOF WITH AN ADENOSINE RECEPTOR ANTAGONIST |
PCT/EP2019/076244 WO2020065036A1 (en) | 2018-09-27 | 2019-09-27 | Use of an inhibitor of an ent family transporter in the treatment of cancer and combination thereof with an adenosine receptor antagonist |
Publications (1)
Publication Number | Publication Date |
---|---|
IL281802A true IL281802A (en) | 2021-05-31 |
Family
ID=68109305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL281802A IL281802A (en) | 2018-09-27 | 2021-03-25 | Use of an inhibitor of an ent family transporter in the treatment of cancer and combination thereof with an adenosine receptor antagonist |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP2022503879A (en) |
BR (1) | BR112021006033A2 (en) |
IL (1) | IL281802A (en) |
WO (1) | WO2020065036A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115873022A (en) | 2017-03-30 | 2023-03-31 | 伊忒欧斯比利时股份公司 | 2-oxothiazole derivatives as A2A inhibitors and compounds for the treatment of cancer |
US11376255B2 (en) | 2018-09-11 | 2022-07-05 | iTeos Belgium SA | Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents |
MX2022006662A (en) * | 2019-12-02 | 2022-07-05 | Astrazeneca Ab | Solid pharmaceutical formulations of 6-(2-chloro-6-methylpyridin- 4-yl)-5-(-4-fluorophenyl)-1,2,4-triazin-3-amine. |
US20240141436A1 (en) | 2021-02-17 | 2024-05-02 | iTeos Belgium SA | Compounds, Compositions and Methods of Treatment Thereof |
CN118076609A (en) * | 2021-10-06 | 2024-05-24 | Iteos比利时公司 | Process for preparing macrocyclic compounds having ENT1 inhibitory activity |
CN118076610A (en) * | 2021-10-06 | 2024-05-24 | Iteos比利时公司 | Macrocyclic compounds with ENT1 inhibitory activity |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007140181A2 (en) * | 2006-05-26 | 2007-12-06 | King Pharmaceuticals Research And Development, Inc. | Combination therapy comprising an adenosine uptake inhibitor and a non-selective adenosine receptor antagonist |
US20090047243A1 (en) * | 2007-07-17 | 2009-02-19 | Richard Rickles | Combinations for the treatment of b-cell proliferative disorders |
GB0906579D0 (en) | 2009-04-16 | 2009-05-20 | Vernalis R&D Ltd | Pharmaceuticals, compositions and methods of making and using the same |
US9291747B2 (en) | 2010-02-08 | 2016-03-22 | Essilor International (Compagnie Generale D'optique) | Optical article comprising an anti-reflecting coating having anti-fogging properties |
ES2365960B1 (en) | 2010-03-31 | 2012-06-04 | Palobiofarma, S.L | NEW ANTAGONISTS OF ADENOSINE RECEPTORS. |
US20130267515A1 (en) * | 2010-10-26 | 2013-10-10 | Alberta Health Services | Combination comprising an atp analog and an adenosine receptor antagonist or a nucleobase/nucleoside analog for the treatment of cancer |
CN110214012B (en) | 2017-01-20 | 2023-05-09 | 艾库斯生物科学有限公司 | Azolopyrimidines for the treatment of cancer related disorders |
TWI801372B (en) | 2017-03-30 | 2023-05-11 | 比利時商艾特歐斯比利時有限公司 | Thiocarbamate derivatives as a2a inhibitors and methods for use in the treatment of cancers |
-
2019
- 2019-09-27 BR BR112021006033-2A patent/BR112021006033A2/en not_active Application Discontinuation
- 2019-09-27 WO PCT/EP2019/076244 patent/WO2020065036A1/en unknown
- 2019-09-27 JP JP2021517484A patent/JP2022503879A/en active Pending
-
2021
- 2021-03-25 IL IL281802A patent/IL281802A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020065036A1 (en) | 2020-04-02 |
JP2022503879A (en) | 2022-01-12 |
BR112021006033A2 (en) | 2021-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL281802A (en) | Use of an inhibitor of an ent family transporter in the treatment of cancer and combination thereof with an adenosine receptor antagonist | |
ZA202100195B (en) | Purinone compounds and their use in treating cancer | |
ZA202002172B (en) | Pde9 inhibitor and use thereof | |
DK3502667T3 (en) | LIGHT DETECTION DEVICES WITH PROTECTIVE LINING AND METHODS IN CONNECTION WITH THE SAME | |
IL279347A (en) | Gremlin-1 antagonist for the prevention and treatment of cancer | |
IL274836A (en) | Dosage regimen of vidofludimus for use in the prevention or treatment of chronic inflammatory and/or autoimmune diseases | |
IL269710A (en) | 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers | |
IL282350A (en) | Rgmc-selective inhibitors and use thereof | |
IL281999A (en) | Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer | |
SG11202102338TA (en) | Quinuclidine-3-one derivatives and their use in cancer treatment | |
IL284053A (en) | Novel compounds and their use in therapy | |
IL276814A (en) | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof | |
PL3899292T3 (en) | Screw with milling-ribs for countersinking the screw and use of the screw | |
IL282527A (en) | Azaindazole-5 derivatives and their use | |
IL277749A (en) | Pladienolide compounds and their use | |
HUE058652T2 (en) | Compounds and their use in the treatment of schistosomiasis | |
IT201700030541A1 (en) | COMPOSITION AND KIT FOR USE IN THE PREVENTION OF RECIDIVATING OPTICOMYOSIS | |
SG11202108832XA (en) | Anti-ang2 antibody and use thereof | |
PL3617533T3 (en) | Screw and its use | |
MX2021003500A (en) | Use of an inhibitor of an ent family transporter in the treatment of cancer and combination thereof with an adenosine receptor antagonist. | |
IL277112A (en) | Compounds for inhibiting protein degradation and methods of use thereof in the treatment of cancer | |
EP3793585A4 (en) | Neoadjuvant cancer treatment with immunotoxin and checkpoint inhibitor combination | |
HK1254107A1 (en) | Anti-trailr2 antibody-toxin-conjugate and use thereof in anti-tumor therapy | |
SG11202103488XA (en) | Galactose rapid quantitative detection system and use thereof | |
GB201815215D0 (en) | Composition and use |